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Abstract
Context—Lynch syndrome is the most common form of hereditary colorectal cancer (CRC) and
is caused by germline mutations in DNA mismatch repair (MMR) genes. Identification of gene
carriers currently relies on germline analysis in patients with MMR-deficient tumors, but criteria
to select individuals in whom tumor MMR testing should be performed are unclear.
Objective—To establish a highly sensitive and efficient strategy for the identification of MMR
gene mutation carriers among CRC probands.
Design, Setting, and Patients—Pooled-data analysis of 4 large cohorts of newly diagnosed
CRC probands recruited between 1994 and 2010 (n = 10 206) from the Colon Cancer Family
Registry, the EPICOLON project, the Ohio State University, and the University of Helsinki
examining personal, tumor-related, and family characteristics, as well as microsatellite instability,
tumor MMR immunostaining, and germline MMR mutational status data.
Main Outcome Measures—Performance characteristics of selected strategies (Bethesda
guidelines, Jerusalem recommendations, and those derived from a bivariate/multivariate analysis
of variables associated with Lynch syndrome) were compared with tumor MMR testing of all
CRC patients (universal screening).
Results—Of 10 206 informative, unrelated CRC probands, 312 (3.1%) were MMR gene
mutation carriers. In the population-based cohorts (n=3671 probands), the universal screening
approach (sensitivity, 100%;95% CI, 99.3%–100%; specificity, 93.0%; 95% CI, 92.0%–93.7%;
diagnostic yield, 2.2%; 95% CI, 1.7%–2.7%) was superior to the use of Bethesda guidelines
(sensitivity, 87.8%; 95% CI, 78.9%–93.2%; specificity, 97.5%; 95% CI, 96.9%–98.0%; diagnostic
yield, 2.0%; 95% CI, 1.5%–2.4%; P <.001), Jerusalem recommendations (sensitivity, 85.4%; 95%
CI, 77.1%–93.6%; specificity, 96.7%; 95% CI, 96.0%–97.2%; diagnostic yield, 1.9%; 95% CI,
1.4%–2.3%; P < .001), and a selective strategy based on tumor MMR testing of cases with CRC
diagnosed at age 70 years or younger and in older patients fulfilling the Bethesda guidelines
(sensitivity, 95.1%; 95% CI, 89.8%–99.0%; specificity, 95.5%; 95% CI, 94.7%–96.1%; diagnostic
yield, 2.1%; 95% CI, 1.6%–2.6%; P <.001). This selective strategy missed 4.9% of Lynch
syndrome cases but resulted in 34.8% fewer cases requiring tumor MMR testing and 28.6% fewer
cases undergoing germline mutational analysis than the universal approach.
Conclusion—Universal tumor MMR testing among CRC probands had a greater sensitivity for
the identification of Lynch syndrome compared with multiple alternative strategies, although the
increase in the diagnostic yield was modest.
Colorectal cancer (CRC) is the third most common cancer worldwide and the second leading
cause of cancer-related death.1 Lynch syndrome, also known as hereditary nonpolyposis
colorectal cancer (HNPCC), is the most common form of hereditary CRC, accounting for
1% to 3% of all these tumors. It is an autosomaldominant disorder caused by germline
mutations in DNA mismatch repair (MMR) genes (ie, MSH2, MLH1, MSH6, and PMS2).2
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The abnormal function of these genes leads to accumulation of errors during DNA
replication, especially in repetitive sequences known as microsatellites. As a result, tumors
of patients with Lynch syndrome characteristically demonstrate MMR deficiency, defined as
the presence of microsatellite instability (MSI) or loss of the MMR protein expression,
which is the hallmark of this disorder.3,4
Identification of patients with Lynch syndrome needs to be improved because, unless there
is strong clinical suspicion, the majority of cases remain undetected, leading to the lack of
implementation of highly effective preventive measures. Indeed, intensive CRC screening
by colonoscopy and prophylactic gynecological surgery have been demonstrated to reduce
both the incidence and mortality of these tumors.5
In 1991, the International Collaborative Group on HNPCC proposed the Amsterdam criteria
and subsequently the extended Amsterdam II criteria,6 the first clinical definition of the
syndrome and as a means to identify the genes responsible. However, these criteria were
limited in clinical practice because of their low sensitivity. Consequently, the National
Cancer Institute proposed the Bethesda guidelines, and more recently the revised Bethesda
guidelines,7 for identifying those individuals who should undergo tumor MSI testing.
Although this strategy has been demonstrated to be both effective and cost-effective,8 it is
not fully accepted because some MMR gene mutation carriers do not fulfill these criteria
and because they are difficult to apply in clinical practice.9 Virtually all Lynch syndrome-
associated CRC display MMR deficiency, so universal tumor MMR screening has been
proposed using MSI testing or immunostaining of all CRC patients.2,4 Recently, it was
suggested that tumor MMR screening should be performed in, at a minimum, all CRC
occurring in individuals younger than 70 years (ie, Jerusalem recommendations).10
Nevertheless, while this strategy overcomes the limitations of using any selection based on
clinical criteria, it might not represent the most effective approach.
The controversy reflects that, at present, tumor MMR testing is the cornerstone for
identification of Lynch syndrome. However, it is still under debate which CRC patients
should undergo these analyses. Most sets of recommendations are not empirically based6,7
or derived from series in which patients were selected on the basis of their personal or
family history.11–14 To overcome these limitations, a pooled data analysis of population-
based series with fully integrated, comprehensive, and reliable data seems the most
appropriate approach to outline a highly sensitive, efficient, and widely accepted strategy for
the identification of MMR gene mutation carriers among CRC probands.
METHODS
The study sample came from the Colon Cancer Family Registry (CFR), the EPICOLON
project,8 the Clinical Cancer Genetics Program of the Ohio State University,4,9 and the
Department of Medical Genetics of the University of Helsinki, Finland15,16 (Figure 1 and
Figure 2). Overall, cases were recruited between 1994 and 2010. The Colon CFR, an
international resource for studies on the etiology of CRC described in detail elsewhere,17
recruited families through 6 administrative centers.18 The EPICOLON, Ohio, and Helsinki
cohorts are population based and represent the core of the comparative analyses of
diagnostic strategies for identification of Lynch syndrome (Figure 2). The Colon CFR
recruited from both population-based cancer registries and through cancer family and high-
risk clinics and used an upper age limit of 75 years (except for the Australian site, which did
not recruit participants older than 60 years).17 Therefore, Colon CFR probands were used
only in the analysis of variables associated with the presence of germline MMR gene
mutations and not in ascertaining the performance characteristics of selected strategies for
Lynch syndrome identification.
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Exclusion criteria were polyposis syndromes and personal history of inflammatory bowel
disease. Written informed consent was obtained from all study participants, and the study
protocol was approved at each participating center.
Personal, tumor-related, and familial characteristics of probands were pooled from each
series. Tumor MSI testing and immunostaining for the 4 MMR proteins were performed as
previously described.4,8,9,15–17,19 MSI testing was done at each center using different panels
of microsatellite markers, and patients were classified as MSI high or MSI-low/
microsatellite stable according to previously described criteria.20 Overall, tumors were
deemed MSI-high if instability was seen at 30% or more markers or instability was present
at monomorphic mononucleotide markers. Tumors were considered MMR deficient if they
were MSI high, exhibited loss of MMR protein expression, or both.
Germline MMR gene testing was performed by both multiple ligation probe amplification
analysis and direct sequencing at each participating center. Whereas MSH2, MLH1, and
MSH6 genes were evaluated in all cohorts, evaluation of the PMS2 gene was not included in
the study design of the cohorts of EPICOLON, Helsinki, and the University of Southern
California Consortium (part of the Colon CFR). Deletions, insertions, duplications,
nonsense, and frame shift mutations were considered deleterious; missense mutations were
considered deleterious based on published data and existing mutation databases. Tumor
MMR status was not used to classify any variant of unknown significance. Germline MMR
mutational analysis was usually driven by demonstration of tumor MMR deficiency,
although in a subset of 187 patients (1.8%), direct germline MMR gene testing was
performed without assessment of MMR status (Figure 1). These patients were used in the
analysis of variables associated with presence of MMR gene mutation but not in ascertaining
the performance characteristics of selected strategies for Lynch syndrome identification.
Similarly, in a subset of 1395 Colon CFR probands, germline gene testing was done
although they had an MMR-proficient tumor. On the other hand, germline MMR gene
testing was not performed in 318 patients (3.1%) in spite of having an MMR deficient tumor
(Figure 1), and consequently, they were excluded from all analyses.
Statistical Analysis
The focus of the analysis was to establish, primarily, the most sensitive strategy and,
secondarily, the most efficient one for identification of MMR gene mutation carriers among
CRC patients. The presence of a germline mutation was considered the gold standard.
Efficiency was defined as the capacity to detect a germline mutation with the minimum
amount of diagnostic resources (ie, tumor MMR testing and germline MMR gene analysis).
Age at diagnosis was treated as a continuous variable. In probands diagnosed with the same
type of cancer more than once, the age at diagnosis of cancer at which they were first
identified as having Lynch syndrome was considered. In relatives diagnosed with the same
type of cancer more than once, the age at diagnosis was defined as the earliest one. The
number of relatives with CRC or other Lynch syndrome–related tumors were also treated as
continuous variables. All other evaluated variables were considered dichotomous.
Logistic regression analysis was performed, adjusted by age, sex, and participating center, to
identify individual variables associated with the presence of germline MMR gene mutations.
Multivariate models based on regression tree analysis were explored to establish the most
discriminative combination of variables to identify MMR gene mutation carriers. Recursive
partitioning programs build classification or regression models of a very general structure
using a 2-stage procedure; the resulting models can be represented as binary trees. Because
the proportion of carriers was low, a high cost for misclassification was used to prime
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sensitivity over specificity. These analyses were limited to probands with information on the
mutational status of MMR genes. Results were expressed as odds ratios (ORs) with 95% CI.
Performance characteristics (ie, sensitivity, specificity, positive and negative predictive
values, positive and negative likelihood ratio, diagnostic yield, and false-positive yield) of
selected strategies for Lynch syndrome identification were calculated with respect to the
presence of germline MMR gene mutations in the population-based cohorts. Selected
strategies included germline testing of probands with an MMR deficient lesion (1) after
tumor testing of any CRC (ie, universal screening strategy); (2) after tumor testing of
patients fulfilling the revised Bethesda guidelines7; (3) after tumor testing of patients
fulfilling the Jerusalem recommendations10; or (4) after tumor testing of patients fulfilling
the model derived from the multivariate analysis. These analyses were performed overall (ie,
mutation in any MMR gene) and for each specific MMR gene. Comparison among
strategies was made using the Matthews correlation coefficient and its 95% CI, which
appropriately weights sensitivity and specificity values, as a measure of the quality of binary
classifications.21
All calculations were performed with SPSS version 18.0 (SPSS) and R package rpart
version 3.1–50.22 All tests were 2-sided, and a P value of less than .05 was considered
statistically significant.
RESULTS
A total of 13 151 unrelated CRC probands from the 4 cohorts were included (Figure 1). Of
these, 2945 cases were excluded due to lack of reliable information on tumor MMR or
germline MMR mutational status. Therefore, 10 206 informative, unrelated CRC probands
constituted the basis of this pooled-data analysis. Demographic, clinical, and tumor-related
characteristics of the patients are summarized in Table 1.
Tumor MMR testing was performed in 10 019 probands (98.1%), whereas in 187 patients
(1.8%), germline MMR gene analysis was done without previous tumor MMR testing
(Figure 1). The number of cases that were tested by MSI only was 2150; by immunostaining
only, 2278; and by both MSI and immunostaining, 5591. In this latter group, concordance
between MSI and immunostaining was 97.5% (94 cases [1.7%] showed MSI with retained
protein expression and 49 [0.8%] exhibited loss of expression with microsatellite stability).
A total of 1386 cases (13.8%) exhibited tumor MMR deficiency. Germline MMR mutational
analysis was completed in 2650 probands and identified 312 gene mutation carriers in MSH2
(n=129), MLH1 (n = 114), MSH6 (n = 40), or PMS2 (n=29), representing 3.1% of the whole
series (individual data available from the authors on request).
Among the 312 probands diagnosed with Lynch syndrome, mean (SD) age at CRC
diagnosis was 48.1 (2.9) years; 131 (42.5%) had 1 or more first-degree relatives with CRC;
41 (14.0%) and 85 (27.2%) fulfilled Amsterdam I and II criteria, respectively; and 214
(68.6%) fulfilled at least 1 criterion of the revised Bethesda guidelines (eTable 1, available
at http://www.jama.com). Moreover, 289 probands (92.6%) exhibited tumor MMR
deficiency, whereas 12 (3.8%) (ie, 5 MLH1, 3 MSH2, 3 MSH6, and 1 PMS2 gene carriers)
showed MMR proficiency. Of those, 5 cases had a tumor retaining protein expression (MSI
analysis not performed), 4 cases exhibited microsatellite stability (immunostaining not
performed), and 3 cases retained protein expression and showed microsatellite stability. In
the remaining 11 probands (3.5%), tumor MMR testing was not performed (eTable 1).
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MMR Gene Mutation Carriers
To identify variables associated with Lynch syndrome, a bivariate analysis was performed in
those probands with information regarding germline MMR mutational status (n=2650)
(Table 2). This analysis identified CRC diagnosed at age 70 years or younger (OR, 4.0; 95%
CI, 2.2–7.1) and fulfillment of at least 1 criterion of the revised Bethesda guidelines (OR,
7.3; 95% CI, 4.6–11.0) as the variables with the highest sensitivity (94.2% and 88.1%,
respectively) and negative predictive value (97.0% and 97.3%, respectively). All other
evaluated characteristics showed sensitivities lower than 70% and negative predictive values
lower than 95% (Table 2). Distribution of germline MMR gene mutations according to the
age at CRC diagnosis is shown in eTable 2.
In the multivariate analysis, based on regression trees, the highest discrimination was
achieved when MMR testing was done for probands with any of the following
characteristics: CRC diagnosed at 60 years or younger, presence of at least 1 first-degree
relative with CRC diagnosed at 50 years or younger, or personal history of metachronous
Lynch syndrome–related tumors diagnosed at 50 years or younger (OR, 11.3; 95% CI, 6.70–
19.0). The sensitivity of this model was 90.1%, with a negative predictive value of 97.5%.
Performance of Selected Strategies
Strategies based on tumor MMR testing of probands fulfilling at least 1 criterion of the
revised Bethesda guidelines, Jerusalem recommendations, the model resulting from the most
sensitive variables in the bivariate analysis (ie, CRC diagnosis at ≤70 years and fulfillment
of at least 1 criterion of the revised Bethesda guidelines, henceforth “selective strategy”), or
the model resulting from the multivariate analysis, followed by germline MMR testing of
individuals with an MMR-deficient tumor, were compared with the universal screening
approach in which tumor MMR testing was performed in all CRC patients (Table 3 and
Table 4). As expected, only the universal screening strategy achieved 100% sensitivity (95%
CI, 99.3%–100%) and negative predictive value (95% CI, 99.9%–100%) in the
identification of patients with Lynch syndrome, when the analysis was limited to population-
based cohorts (n=3671) (Figure 2).
Universal tumor testing (sensitivity, 100%; 95% CI, 99.3%–100%; specificity, 93.0%; 95%
CI, 92.0%–93.7%; diagnostic yield, 2.2%; 95% CI, 1.7%–2.7%) was superior to the
selective strategy (sensitivity, 95.1%; 95% CI, 89.8%–99.0%; specificity, 95.5%; 95% CI,
94.7%–96.1%; diagnostic yield, 2.1%; 95% CI, 1.6%–2.6%; Matthews correlation
coefficient, 0.54; P<.001), Bethesda guidelines (sensitivity, 87.8%; 95% CI, 78.9%–93.2%;
specificity, 97.5%; 95% CI, 96.9%–98.0%; diagnostic yield, 2.0%; 95% CI, 1.5%–2.4%;
Matthews correlation coefficient, 0.61; P <.001), and Jerusalem recommendations
(sensitivity, 85.4%; 95% CI, 77.1%–93.6%; specificity, 96.7%; 95% CI, 96.0%–97.2%;
diagnostic yield, 1.9%; 95% CI, 1.4%–2.3%; Matthews correlation coefficient, 0.55; P<.
001) (Table 3 and Table 4). However, differences in diagnostic yield from the universal
approach were small, with a difference between universal screening and the next less
intensive strategy (ie, selective strategy) of only 0.11% (Table 3 and Table 4) and
accompanied by an increase in false-positive yield of 2.5%. Indeed, the selective strategy
resulted in a 34.8% fewer CRC patients requiring tumor MMR testing and an additional
28.6% fewer cases undergoing germline MMR mutational analysis in comparison with
universal screening (Table 3 and Table 4). All these results were similar to those obtained in
the overall series (eTable 3).
When the analysis was conducted for each specific MMR gene, the selective strategy
resulted in identical sensitivity and negative predictive value to those achieved with the
universal tumor MMR testing approach but only for the identification of MLH1 and MSH2
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gene carriers, in a similar manner as the fulfillment of Bethesda guidelines for the
identification of MLH1 gene carriers (Table 5). Again, these results were similar to those
obtained in the whole series (eTable 4).
COMMENT
Results of this international, multicenter, pooled-data analysis demonstrate that unless a
universal screening approach consisting of tumor MMR testing in all CRC patients is
performed, a clinically meaningful proportion of MMR gene mutation carriers will remain
undiagnosed. Specifically, use of the revised Bethesda guidelines will miss approximately
12%, use of the Jerusalem recommendations will miss approximately 15%, and use of a
selective criteria (performing tumor MMR testing of CRC probands diagnosed at 70 years or
younger or fulfilling ≥ 1 criterion of the revised Bethesda guidelines) will miss
approximately 5%. Conversely, the specificity for these strategies ranged from 93.0% for the
universal tumor MMR testing approach to 97.5% for the Bethesda guidelines. These data
may be useful to more empirically inform discussions on the most efficient approaches for
the identification of Lynch syndrome among CRC probands.
This study has several strengths. First, this is the largest series published so far in which
fully characterized CRC patients were evaluated to ascertain the most effective and efficient
strategy for the identification of Lynch syndrome, using personal and family history, tumor
MMR testing, and germline MMR mutational data. This comprehensive approach
overcomes previous attempts—Amsterdam criteria,6,23 Bethesda guidelines,7 and Jerusalem
recommendations10—in which strategies were not empirical or were based on expert
consensus. Second, this analysis was based on population-based cohorts,4,8,9,15,16 its results
being applicable to an unremarkable newly diagnosed CRC patient rather than in the subset
of individuals usually referred to genetic counseling because of a high suspicion of an
inherited disorder. Third, the methodological approach, which included an exploratory
analysis of the most discriminative variables associated with presence of germline MMR
mutations and evaluation of the performance characteristics of comprehensive strategies,
allowed us not only to establish their accuracy for the identification of Lynch syndrome, but
also to estimate the molecular resources needed.
We are aware of some limitations of the study. First, the results of this investigation have
not been replicated in an independent set of CRC patients because the prevalence of Lynch
syndrome is relatively low and, accordingly, it is difficult to find 2 database sets adequate
for such analyses. Second, all probands were diagnosed with CRC, thus precluding our
ability to extrapolate our results to patients presenting with other Lynch syndrome–related
tumors. Nevertheless, CRC represents the most prevalent neoplasm in such patients, and in
fact, it is the most common “red flag” to drive the subsequent molecular confirmation.24,25
Third, germline MMR mutational analysis was not performed in all probands, although it
was done in the vast majority of patients with MMR-deficient tumors and also in a notable
proportion of those with proficient lesions. In that sense, it is important to note that 12
mutation carriers had an MMR-proficient neoplasm, thus indicating that a reduced number
of patients with Lynch syndrome will remain undiagnosed if screening relies on MMR
tumor testing. To overcome this limitation, sequencing all genes of concern in all CRC
patients would represent the most sensitive approach. When high-throughput technology
becomes more affordable, cost-effectiveness analysis of this approach will be warranted.
Fourth, no information was available regarding either tumor BRAF V600E mutation or
tumor MLH1 gene promoter methylation. Both molecular techniques are helpful in
excluding epigenetically driven inactivation of the MLH1 gene among patients with MLH1-
deficient tumors.26 This fact may explain the lower specificity of all evaluated strategies for
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the identification of MLH1 gene carriers with respect to the other 3 MMR genes, but it does
not affect their sensitivity, which is the main goal of our analysis. Finally, in contrast to the
other 3 MMR genes, the PMS2 gene was not systematically analyzed in all evaluated
cohorts. This limitation, however, has been addressed by analyzing the results separately for
each specific gene.
Our analysis demonstrates that, although the revised Bethesda guidelines have been
considered as the mainstay for selecting patients to undergo tumor MMR testing so
far,7,8,27,28 they have a low sensitivity for the identification of Lynch syndrome. The lack of
sensitivity is mainly due to its poor performance in identifying MSH6 gene carriers29 and, to
less extent, PMS2 and MSH2 gene carriers. On the other hand, the use of age at CRC
diagnoses as a criterion to select patients requiring tumor MMR testing, as was suggested in
the Lynch syndrome conference held in Jerusalem,10 is also limited by a low sensitivity,
because 15% of patients were older than 70 years at the diagnosis of Lynch syndrome.
Universal tumor screening has, as expected, the highest sensitivity. Although it is not
sufficient to just consider sensitivity when comparing different strategies, this is the most
important parameter clinically (ie, to minimize the number of patients with undiagnosed
Lynch syndrome). Indeed, it is accepted that the whole Lynch syndrome screening process is
cost-effective when the benefits to immediate relatives of identified patients are
considered30; accordingly, the more patients who are diagnosed, the more atrisk relatives
can undergo genetic evaluation and receive appropriate cancer surveillance and other
preventive interventions.
On the other hand, any policy recommendation needs to consider the economic and
psychosocial harms of false-positive results obtained in each strategy. It is notable that the
selective strategy of performing tumor MMR testing of CRC probands diagnosed at 70 years
or younger, and in older probands fulfilling at least 1 criterion of the revised Bethesda
guidelines, achieved a similar diagnostic yield to the universal strategy, while reducing by
about 35% and 30% the number of patients requiring tumor and germline MMR testing,
respectively. Therefore, if resources are limited, this selective strategy may represent an
alternative approach to universal tumor screening for the identification of Lynch syndrome,
although it remains to be demonstrated that this strategy can be implemented consistently in
a clinical setting. Whereas recent data suggest that universal tumor testing may yield
substantial benefits at acceptable costs,31 further studies assessing cost-effectiveness of
those strategies evaluated in this study are still needed.
In addition to the pragmatic approach proposed in this study, a more precise characterization
of probands exhibiting MLH1-deficient tumors is needed. Because tumor MMR deficiency
in the vast majority of such patients is due to epigenetic MLH1 inactivation, performance of
tumor BRAF V600E mutation analysis,32,33 or even better, methylation analysis of MLH1
gene promoter,34,35 may contribute to increasing the specificity of this strategy for the
identification of MLH1 gene carriers and consequently to further decreasing the cost
associated with germline testing.
The strategies evaluated in this study rely heavily on tumor testing. However, they should
not be in conflict with available mathematical algorithms to predict MMR gene mutation
carriers based on personal and family history.11–14,36–38 Indeed, both approaches must be
viewed as complementary because it is not always feasible to obtain tumor tissue.36,39 More
importantly, these models may also encompass individuals affected by other non-CRC
Lynch syndrome–related tumors.11–14,36–38 In addition, it would be interesting to explore
whether the use of predictive algorithms may contribute to identifying gene mutation
carriers among patients with MMR-proficient tumors.
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Finally, it is important to note that significant differences were observed among the 3
population-based cohorts evaluated in this study. Indeed, in the EPICOLON cohort, the
prevalence of Lynch syndrome, as well as of tumor MMR deficiency, was roughly half that
observed in the Ohio and Helsinki series. This finding, rather than being considered as a
drawback of our analysis, should be regarded as an opportunity to generalize its results
broadly. The geographical variation in Lynch syndrome genotypic and phenotypic
characteristics4,8,9,15–17 may reflect some specific gene-environment interactions and
therefore deserves further investigation.
In conclusion, identification of patients with Lynch syndrome is critical to drive
presymptomatic diagnosis of relatives at risk, as well as subsequent preventive measures for
decreasing morbidity and mortality. Universal tumor MMR testing followed by germline
testing offers the highest sensitivity and a somewhat lower specificity than alternative
screening strategies for this purpose, although the increase in the diagnostic yield is modest.
The empirical data from this large multinational study may help inform clinical
recommendations for individuals diagnosed with CRC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Funding/Support: This work was supported by grants from the Ministerio de Economía y Competividad
(SAF2010-19273), Agència de Gestió d'Ajuts Universitaris i de Recerca (2009 SGR 849), Asociación Española
contra el Cáncer (Fundación Científica and Junta de Barcelona), Hospital Clínic of Barcelona (Josep Font grant),
and Instituto de Salud Carlos III (PI10/00384). CIBEREHD and CIBERESP are funded by the Instituto de Salud
Carlos III. The research at the Ohio State University Comprehensive Cancer Center was supported by National
Cancer Institute grants CA67941 and CA16058. The research at the University of Pennsylvania was supported by
the National Institutes of Health under 5R01DK056645, the National Colon Cancer Research Alliance, and the
Hansen Foundation. This work was also supported by the National Cancer Institute, by the National Institutes of
Health under RFA CA-95-011, and through cooperative agreements with members of the Colon Cancer Family
Registry and Principal Investigators. Collaborating centers include Australasian Colorectal Cancer Family Registry
(U01 CA097735), Familial Colorectal Neoplasia Collaborative Group (U01 CA074799) (University of Southern
California), Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (U01 CA074800), Ontario
Registry for Studies of Familial Colorectal Cancer (U01 CA074783), Seattle Colorectal Cancer Family Registry
(U01 CA074794), and University of Hawaii Colorectal Cancer Family Registry (U01 CA074806). The work was
carried out in part at the Esther Koplowitz Center, Barcelona.
Role of the Sponsor: The funding sources had no role in the design and conduct of the study; in the collection,
analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript
Additional Contributions: We thank all study participants of the Colon Cancer Family Registry, the Ohio State
University, the University of Helsinki, and the EPICOLON consortium and corresponding staff for their
contributions to this project. None of them were compensated for their contributions.
REFERENCES
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;
59(4):225–249. [PubMed: 19474385]
2. Vasen HF, Boland CR. Progress in genetic testing, classification, and identification of Lynch
syndrome. JAMA. 2005; 293(16):2028–2030. [PubMed: 15855438]
3. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003; 348(10):919–932.
[PubMed: 12621137]
4. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among
patients with colorectal cancer. J Clin Oncol. 2008; 26(35):5783–5788. [PubMed: 18809606]
Moreira et al. Page 9













5. Stoffel EM, Chittenden A. Genetic testing for hereditary colorectal cancer: challenges in identifying,
counseling, and managing high-risk patients. Gastroenterology. 2010; 139(5):1436–1441. [PubMed:
20858494]
6. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis
colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on
HNPCC. Gastroenterology. 1999; 116(6):1453–1456. [PubMed: 10348829]
7. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis
colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004; 96(4):
261–268. [PubMed: 14970275]
8. Piñol V, Castells A, Andreu M, et al. Gastrointestinal Oncology Group of the Spanish
Gastroenterological Association. Accuracy of revised Bethesda guidelines, microsatellite instability,
and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal
cancer. JAMA. 2005; 293(16):1986–1994. [PubMed: 15855432]
9. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary
nonpolyposis colorectal cancer). N Engl J Med. 2005; 352(18):1851–1860. [PubMed: 15872200]
10. Boland CR, Shike M. Report from the Jerusalem workshop on Lynch syndrome-hereditary
nonpolyposis colorectal cancer. Gastroenterology. 2010; 138(7):2197. e1-e7. [PubMed: 20416305]
11. Balmaña J, Stockwell DH, Steyerberg EW, et al. Prediction of MLH1 and MSH2 mutations in
Lynch syndrome. JAMA. 2006; 296(12):1469–1478. [PubMed: 17003395]
12. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations
in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006; 354(26):2751–2763.
[PubMed: 16807412]
13. Chen S, Wang W, Lee S, et al. Colon Cancer Family Registry. Prediction of germline mutations
and cancer risk in the Lynch syndrome. JAMA. 2006; 296(12):1479–1487. [PubMed: 17003396]
14. Wijnen JT, Vasen HF, Khan PM, et al. Clinical findings with implications for genetic testing in
families with clustering of colorectal cancer. N Engl J Med. 1998; 339(8):511–518. [PubMed:
9709044]
15. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer
and the feasibility of molecular screening for the disease. N Engl J Med. 1998; 338(21):1481–
1487. [PubMed: 9593786]
16. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary
nonpolyposis colorectal cancer. J Clin Oncol. 2000; 18(11):2193–2200. [PubMed: 10829038]
17. Newcomb PA, Baron J, Cotterchio M, et al. Colon Cancer Family Registry. Colon Cancer Family
Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer
Epidemiol Biomarkers Prev. 2007; 16(11):2331–2343. [PubMed: 17982118]
18. Breast and colon cancer family registries. National Cancer Institute; http://epi.grants.cancer.gov/
CFR/. [Accessed September 25, 2012]
19. Cicek MS, Lindor NM, Gallinger S, et al. Quality assessment and correlation of microsatellite
instability and immunohistochemical markers among population- and clinic-based colorectal
tumors results from the Colon Cancer Family Registry. J Mol Diagn. 2011; 13(3):271–281.
[PubMed: 21497289]
20. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on
Microsatellite Instability for cancer detection and familial predisposition: development of
international criteria for the determination of microsatellite instability in colorectal cancer. Cancer
Res. 1998; 58(22):5248–5257. [PubMed: 9823339]
21. Baldi P, Brunak S, Chauvin Y, Andersen CA, Nielsen H. Assessing the accuracy of prediction
algorithms for classification: an overview. Bioinformatics. 2000; 16(5):412–424. [PubMed:
10871264]
22. Therneau, TM.; Atkinson, B. [Accessed September 21, 2012] R port. http://CRAN.R-project.org/
package=rpart
23. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary
Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991; 34(5):424–425.
[PubMed: 2022152]
Moreira et al. Page 10













24. Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M, Järvinen HJ. Life-time risk of different
cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995;
64(6):430–433. [PubMed: 8550246]
25. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and
clinical implications. Ann Intern Med. 2003; 138(7):560–570. [PubMed: 12667026]
26. Loughrey MB, Waring PM, Tan A, et al. Incorporation of somatic BRAF mutation testing into an
algorithm for the investigation of hereditary nonpolyposis colorectal cancer. Fam Cancer. 2007;
6(3):301–310. [PubMed: 17453358]
27. Rodríguez-Moranta F, Castells A, Andreu M, et al. Gastrointestinal Oncology Group of the
Spanish Gastroenterological Association. Clinical performance of original and revised Bethesda
guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed
colorectal cancer: proposal of a new and simpler set of recommendations. Am J Gastroenterol.
2006; 101(5):1104–1111. [PubMed: 16696788]
28. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an
inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006; 296(12):1507–
1517. [PubMed: 17003399]
29. Wu Y, Berends MJ, Mensink RG, et al. Association of hereditary nonpolyposis colorectal cancer-
related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J
Hum Genet. 1999; 65(5):1291–1298. [PubMed: 10521294]
30. Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of
microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal
cancer. Ann Intern Med. 2001; 135(8 pt 1):577–588. [PubMed: 11601929]
31. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among
patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011; 155(2):69–
79. [PubMed: 21768580]
32. Bessa X, Ballesteé B, Andreu M, et al. Gastrointestinal Oncology Group of Spanish
Gastroenterological Association. A prospective, multicenter, population-based study of BRAF
mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol. 2008; 6(2):206–
214. [PubMed: 18096441]
33. Domingo E, Niessen RC, Oliveira C, et al. BRAF-V600E is not involved in the colorectal
tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene. 2005;
24(24):3995–3998. [PubMed: 15782118]
34. Payá A, Alenda C, Pérez-Carbonell L, et al. Utility of p16 immunohistochemistry for the
identification of Lynch syndrome. Clin Cancer Res. 2009; 15(9):3156–3162. [PubMed: 19383812]
35. Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRAF
mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a
literature review assessing utility of tumour features for MMR variant classification. J Med Genet.
2012; 49(3):151–157. [PubMed: 22368298]
36. Balaguer F, Balmaña J, Castellví-Bel S, et al. Gastrointestinal Oncology Group of the Spanish
Gastroenterological Association. Validation and extension of the PREMM1,2 model in a
population-based cohort of colorectal cancer patients. Gastroenterology. 2008; 134(1):39–46.
[PubMed: 18061181]
37. Kastrinos F, Steyerberg EW, Mercado R, et al. The PREMM(1,2,6) model predicts risk of MLH1,
MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology. 2011; 140(1):
73–81. [PubMed: 20727894]
38. Kastrinos F, Syngal S. Inherited colorectal cancer syndromes. Cancer J. 2011; 17(6):405–415.
[PubMed: 22157284]
39. Balmaña J, Balaguer F, Castellví-Bel S, et al. Gastrointestinal Oncology Group of the Spanish
Gastroenterological Association. Comparison of predictive models, clinical criteria and molecular
tumour screening for the identification of patients with Lynch syndrome in a population-based
cohort of colorectal cancer patients. J Med Genet. 2008; 45(9):557–563. [PubMed: 18603628]
Moreira et al. Page 11














Flowchart of the Study for the Overall Series
A patient is assumed to not have Lynch syndrome if the tumor is mismatch repair (MMR)
proficient; germline MMR gene analysis was not performed for most of these individuals.
CRC indicates colorectal cancer.
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Flowchart of the Study for the Population-Based Cohorts
A patient is assumed to not have Lynch syndrome if the tumor is mismatch repair (MMR)
proficient; germline MMR gene analysis was not performed for most of these individuals.
CRC indicates colorectal cancer.
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